Rigel Pharmaceuticals Enters Licensing Agreement with Arvinas and Pfizer for Breast Cancer Drug
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize the breast cancer drug VEPPANU. The deal includes Rigel contributing up to $40 million over four years, potentially boosting its revenue growth.
Topics: breast cancer drug FDA approval licensing PROTAC technology